- Conditions
- SARS-CoV-2
- Interventions
- SPIKEVAX
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15,196,685 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–43
of 43
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273.214, Placebo
- Biological · Other
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Months to 6 Months
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 39
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
- Conditions
- X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273, Placebo, mRNA-1273.351
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Savannah, Georgia • Newton, Kansas • Kansas City, Missouri + 5 more
- Conditions
- COVID-19, Pregnancy; Infection
- Interventions
- mRNA COVID-19 vaccine (Pfizer or Moderna)
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Kidney Transplant Recipients, Liver Transplant Recipients
- Interventions
- Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- Influenza Immunization, Healthy Volunteers
- Interventions
- Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • San Diego, California • Vista, California + 3 more
- Conditions
- SARS-CoV-2
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 50,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fever After Vaccination, Fever, Seizures Fever
- Interventions
- mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- COVID-19, Long Haul
- Interventions
- Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
- Drug · Diagnostic Test · Biological + 3 more
- Lead sponsor
- Well- Konnect Healthcare Services and Research Firm
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID-19
- Interventions
- Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 10
- States / cities
- Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo, mRNA-1273.222
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 4,328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 48
- States / cities
- Banning, California • La Mesa, California • Lake Worth, Florida + 41 more
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Interventions
- mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
- Conditions
- COVID-19, Corona Virus Infection
- Interventions
- Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine
- Biological
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- COVID-19 Pneumonia, COVID-19
- Interventions
- Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Covid19
- Interventions
- Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 11 more
- Conditions
- Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
- Interventions
- mRNA-1273 (Moderna COVID-19 vaccine)
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo, mRNA-1273.214
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 11,942 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more